Kevin Wilson

Company: Foghorn Therapeutics

Job title: Vice President & Head of Chemistry

Seminars:

Roundtable Discussion: Discussing Critical Challenges Faced in Clinical Trials for Degraders 9:30 am

How can we best use preclinical data to predict the right dose and dosing regimen? How can we best confirm PK/PD/Efficacy a clinical in clinical study?Read more

day: Day Two Until 10am

Expanding the Therapeutic Frontier: Targeted Protein Degradation in the Chromatin Regulatory System 9:15 am

Unlocking the therapeutic potential of chromatin-regulating proteins through targeted protein degradation, with a focus on developing novel approaches to modulate gene expression pathways implicated in disease Highlighting key advancements in Foghorn’s degrader pipeline, emphasizing innovative strategies to optimize selectivity and potency while addressing drug resistance challenges Demonstrating how enhanced degrader optionality broadens therapeutic applications and…Read more

day: Day 1 - Until 10:15